Colm White is an accomplished global drug development and program leadership executive with extensive experience across clinical development, regulatory strategy and R&D operations. He most recently was at Takeda Pharmaceuticals, serving as Vice President, Global Program Leader for Vedolizumab, managing its worldwide launch and the delivery of its clinical program, including the successful head-to-head-trial versus Humira. Colm also led portfolio operations in drug discovery, building a team of over 100 scientists to partner and in-license new GI therapies. In addition, he led the re-design program for all R&D lab operations. Prior to this, he served as program leader for the Phase III trials, FDA & EMA filing and approval of certolizumab pegol (anti-TNF antibody from UCB-Celltech) in rheumatoid arthritis and Crohn’s disease, and led the FDA resubmission and EMA approval process for Defitelio, a hematology drug subsequently sold to Jazz Pharmaceuticals. Colm has prepared and led EMA & FDA meetings, managing budgets ranging from $500 million in big pharma to $12 million in smaller biotech. Earlier in his career, Colm spent 9 years in pharma R&D consulting at PwC, working on extensive re-engineering programs with AstraZenca, GE Healthcare, and Novartis. Colm holds a BS in Biotechnology from Dublin City University.